

**DEVELOPING INDIVIDUALISED THERAPY FOR
COLISTIN THROUGH APPLICATION OF
PHARMACOKINETIC MODEL TAILORED
FOR CRITICALLY ILL MALAYSIAN
PATIENTS UTILIZING THE HPLC-FLD**

MOHD SHAFIE BIN ZABIDI

UNIVERSITI SAINS MALAYSIA

2025

**DEVELOPING INDIVIDUALISED THERAPY FOR
COLISTIN THROUGH APPLICATION OF
PHARMACOKINETIC MODEL TAILORED
FOR CRITICALLY ILL MALAYSIAN
PATIENTS UTILIZING THE HPLC-FLD**

by

MOHD SHAFIE BIN ZABIDI

Thesis submitted in fulfilment of the requirements

for the degree of

Doctor of Philosophy

FEBRUARY 2025

ACKNOWLEDGEMENT



All praises are to Allah, the Almighty, for giving me the courage to undertake and complete this study. I would like to express my deepest appreciation and thanks to my main supervisor, Dr Wan Nazirah Wan Yusuf, for her constant support, guidance, patience, motivation, and immense knowledge of my PhD journey. I would like to thank my co-supervisors, Dr Ruzilawati Abu Bakar, Dr Nurfadhlina Musa, and Dr Suzana Mustafa, for their support, encouragement, and invaluable suggestions for their continuous help and guidance. My warmest thanks also go to Puan Norzihana Ramli, Encik Mohd Lukman Muhamad, Encik Wan Mohd Hafiz Wan Anor and all staff members of the Laboratory Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, for their continuous support and help.

Finally, my deepest gratitude goes to my beloved wife, Dr Nur Fadhlina Arifin, and my son, Ahmad Ammar Mohd Shafie, who are pillars behind my achievement. This thesis is dedicated to my late mother, Allahyarhamah Hajah Rokiah Abdullah and my father Haji Zabidi Ishak, for their encouragement, prayers, unconditional love and understanding.

This research was funded by a Universiti Sains Malaysia (USM) Bridging Grant (No: 304.PPSP.6316240) and a GIPS-PhD Grant (No: 311/PPSP/4404810). I am grateful to the Malaysia Ministry of Health for funding my study under Hadiah Latihan Persekutuan.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS.....	iii
LIST OF TABLES	xi
LIST OF FIGURES	xiv
LIST OF SYMBOLS	xvii
LIST OF ABBREVIATIONS	xviii
LIST OF APPENDICES	xxi
ABSTRAK	xxii
ABSTRACT	xxiv
CHAPTER 1 INTRODUCTION.....	1
1.1 Overview	1
1.2 Problem statement	3
1.3 Objectives.....	7
1.3.1 General objective.....	7
1.3.2 Specific objectives.....	7
1.4 Justification of the study	8
1.5 Conceptual framework	9
1.6 Significance of the study	10
CHAPTER 2 LITERATURE REVIEW.....	11
2.1 Introduction	11
2.2 Critically ill patients	12
2.2.1 Definition	12
2.2.2 Antibiotic pharmacokinetics alteration in the critically ill patients	13

2.3	Polymyxin antibiotic	15
2.3.1	Chemical structure.....	15
2.3.2	Mechanism of antibacterial activity of polymyxins.....	20
2.4	Bioassay of colistin methanesulfonate sodium and colistin.....	20
2.4.1	Microbiological assay	20
2.4.2	High-performance liquid chromatography with fluorimetry detection (HPLC-FLD)	21
2.4.3	Liquid chromatography-tandem mass spectrometry (LC-MS).....	22
2.5	Population pharmacokinetics of colistin methanesulfonate sodium and colistin in critically ill patients.....	28
2.5.1	Concentration of colistin methanesulfonate sodium and colistin in plasma after colistin methanesulfonate sodium administration.....	29
2.5.1(a)	Concentration of colistin in patients with preserved renal function.	30
2.5.1(b)	Concentration of colistin in plasma after application of loading dose.....	32
2.5.1(c)	Concentration of colistin in patients with renal impairment and patients receiving renal replacement therapy	36
2.5.2	Pharmacokinetic parameters of colistin methanesulfonate sodium and colistin in critically ill patients.	38
2.5.2(a)	Volume of distribution (V_d).....	42
2.5.2(b)	Clearance (CL).....	43
2.5.2(c)	Elimination half-life ($t_{1/2}$)	44
2.6	Individualised dosing of colistin for critically ill patients.....	46
2.6.1	Population pharmacokinetics modelling	46
2.6.2	Pmetrics software	48
2.7	Summary	50

CHAPTER 3	METHODOLOGY.....	52
3.1	Introduction	52
3.1.1	Chemical and solvent	52
3.1.2	Instruments and materials.....	52
3.2	High-performance liquid chromatography (HPLC) method development and validation for measuring colistin in human plasma.	57
3.2.1	Preparation of chemical and reagents.....	57
3.2.1(a)	Preparation of boric acid 0.6M	57
3.2.1(b)	Preparation of carbonate buffer (1%, w/w, pH 10)	57
3.2.1(c)	Preparation of 9-fluorenylmethyl chloroformate (Fmoc-Cl), 100mM.....	58
3.2.1(d)	Preparation of methanol 95%	58
3.2.1(e)	Preparation of methanol-0.1% formic acid.....	58
3.2.2	Drug-free human plasma and serum for HPLC method development	58
3.2.3	Preparation of stock solution and working solution for colistin and CMS.....	59
3.2.4	Preparation of HPLC calibrators	61
3.2.5	Development of quadrupole time-of-flight liquid chromatography-mass spectrometry (QTOF-LC/MS) method for colistin in human plasma	62
3.2.5(a)	Preparation of mobile phase (Acetonitrile-0.1% formic acid, water-0.1% formic acid).....	62
3.2.5(b)	Sample pre-treatment.....	62
3.2.5(c)	Chromatographic optimisation parameters.....	63
3.2.5(d)	Mass spectrometry optimisation parameters	64
3.2.5(e)	Recovery	66
3.2.5(f)	Precision	66

3.2.6	Development of high-performance liquid Chromatography with fluorescence detection (HPLC-FLD) method for measuring colistin in human serum.....	67
3.2.6(a)	Preparation of mobile phase (Acetonitrile: tetrahydrofuran: water, 80%:4%:6%, v/v/v).....	67
3.2.6(b)	Sample pre-treatment for colistin	67
3.2.6(c)	Protein precipitation.....	68
3.2.6(d)	Solid Phase Extraction Procedure.....	68
3.2.6(e)	Chromatographic optimisation parameters.....	70
3.2.6(f)	Method validation.....	72
3.3	Population pharmacokinetics model development and validation of colistin in critically ill patients.....	76
3.3.1	Meta-analysis data set of colistin in critically ill patients for model development group.....	78
3.3.1(a)	Search strategy and study selection	78
3.3.1(b)	Eligibility criteria.....	78
3.3.1(c)	Inclusion and exclusion criteria	81
3.3.1(d)	Data extraction for meta-analysis	81
3.3.1(e)	Data quality assessment.....	82
3.3.1(f)	Meta-analysis data set of colistin.....	83
3.3.2	Pharmacokinetic sampling of colistin in Malaysian critically ill patients for model validation group	84
3.3.2(a)	Sample size calculation.....	84
3.3.2(b)	Subject recruitment for the model validation group	85
3.3.2(c)	Ethics approval	85
3.3.2(d)	Colistin methanesulfonate sodium administration.....	87
3.3.2(e)	Pharmacokinetic sampling.....	89
3.3.2(f)	Adverse event	91
3.3.2(g)	Serum colistin concentration measurement.....	91

3.3.3	Population pharmacokinetics model development.....	92
3.3.3(a)	Structural model for colistin	92
3.3.3(b)	Covariate model for colistin	92
3.3.3(c)	Population pharmacokinetics model validation.....	93
3.4	Individualised dosing of colistin methanesulfonate sodium in critically ill patients	95
CHAPTER 4 RESULTS.....		97
4.1	High-performance liquid chromatography (HPLC) method development and validation for measuring colistin in human plasma.	97
4.1.1	Development of quadrupole time-of-flight liquid chromatography-mass spectrometry (QTOF-LC/MS) for colistin in human plasma.....	97
4.1.1(a)	Sample pre-treatment.....	97
4.1.1(b)	Optimisation of chromatographic condition.....	98
4.1.1(c)	Optimisation of mass spectrometry condition	102
4.1.1(d)	Final liquid chromatography and mass spectrometry condition	108
4.1.1(e)	Extraction recovery.....	109
4.1.2	Development of high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method for measuring colistin in human serum.....	110
4.1.2(a)	Optimisation of sample pre-treatment procedure	110
4.1.2(b)	Final protein precipitation and solid phase extraction procedure	113
4.1.2(c)	Optimisation of high-performance liquid chromatography	114
4.1.2(d)	Final liquid chromatography condition	119
4.1.2(e)	Method validation.....	119
4.1.2(f)	Application of the HPLC-FLD method to clinical samples	127

4.2	Population pharmacokinetics model development and validation of colistin in critically ill patients	130
4.2.1	Meta-analysis data set of colistin in critically ill patients for the model development group.....	130
4.2.1(a)	Study selection and study eligibility.....	130
4.2.1(b)	Data quality assessment.....	130
4.2.1(c)	Demographic study and patient characteristics	134
4.2.1(d)	Meta-analysis data set of colistin.....	136
4.2.2	Pharmacokinetic sampling of colistin in Malaysian critically ill patients for model validation group.	137
4.2.2(a)	Patient demographic data.....	137
4.2.2(b)	Colistin methanesulfonate sodium administration.....	137
4.2.2(c)	Pharmacokinetic sampling.....	140
4.2.2(d)	Serum colistin concentration measurement.	141
4.2.3	Population pharmacokinetics model development.....	142
4.2.3(a)	Structural model for colistin	144
4.2.3(b)	Covariate model for colistin	146
4.2.3(c)	Final model for colistin.....	147
4.2.4	Population pharmacokinetics model validation	150
4.2.4(a)	Internal validation.....	150
4.2.4(b)	External validation.....	151
4.2.5	Population pharmacokinetics parameter of colistin in Malaysian critically ill patients.	153
4.3	Individualised dosing of colistin methanesulfonate sodium in critically ill patients.	155
CHAPTER 5 DISCUSSION		160
5.1	High-performance liquid chromatography (HPLC) development and validation for measuring colistin in human plasma.....	160

5.1.1	Development of quadrupole time-of-flight liquid chromatography-mass spectrometry (QTOF-LC/MS) method for quantification of colistin in human plasma.....	162
5.1.1(a)	Sample pre-treatment.....	162
5.1.1(b)	Optimisation of chromatographic condition.....	163
5.1.1(c)	Optimisation of mass spectrometry condition	165
5.1.1(d)	Extraction recovery.....	167
5.1.2	Development and validation of high-performance liquid Chromatography with fluorescence detection (HPLC-FLD) method for measuring colistin in human serum.	168
5.1.2(a)	Optimisation of sample pre-treatment procedure	168
5.1.2(b)	Optimisation of colistin derivatisation in SPE.....	170
5.1.2(c)	Optimisation of high-performance liquid chromatography	171
5.1.2(d)	Method validation.....	173
5.2	Population pharmacokinetics model development and validation of colistin in critically ill patients.	177
5.2.1	Meta-analysis data set of colistin in critically ill patients for model development group.....	179
5.2.2	Pharmacokinetic sampling in Malaysian critically ill patients for model validation.	180
5.2.3	Population pharmacokinetics model development.....	182
5.2.4	Population pharmacokinetics model validation	185
5.2.5	Population pharmacokinetics of colistin in Malaysian critically ill patients	187
5.3	Individualised dosing of colistin methanesulfonate sodium in critically ill patients.	192
5.4	Study limitation and recommendation for future research.....	198

CHAPTER 6	CONCLUSION.....	201
REFERENCES.....		204
APPENDICES		

LIST OF TABLES

	Page
Table 2.1 Bioanalysis of CMS and/or colistin in biological fluid using HPLC with fluorimetry detection method.....	23
Table 2.2 Bioanalysis of CMS and/or colistin in biological fluid using LC- MS/MS method	25
Table 2.3 Comparison of CMS and colistin concentration in plasma after administration of the first dose of CMS.....	31
Table 2.4 CMS pharmacokinetic parameters in plasma at steady state	39
Table 2.5 Colistin pharmacokinetic parameters in plasma steady state.....	40
Table 2.6 CMS and colistin pharmacokinetic parameters in plasma steady- state patients receiving renal replacement therapy.....	41
Table 3.1 List of chemicals and solvents used in the study.	54
Table 3.2 List of instruments and materials used in the study.	55
Table 3.3 Low-concentration colistin sulphate calibrators and QC preparation.....	61
Table 3.4 The colistin sulphate calibrators and QC preparation.	61
Table 3.5 The experiment conducted for optimisation of QTOF-LC/MS conditions	65
Table 3.6 Optimisation parameters and experiments for HPLC-FLD- analysis.....	71
Table 3.7 Scope of literature review	79
Table 3.8 Quality assessment criteria.....	83
Table 3.9 Inclusion and exclusion criteria of the study.....	85
Table 3.10 Loading dose of colistin methanesulfonate sodium	87
Table 3.11 Maintenance dose of colistin methanesulfonate sodium.....	88

Table 4.1	Gradient of the elution program.....	108
Table 4.2	Results of the extraction recovery of colistin A, colistin B and polymyxin B.....	109
Table 4.3	Final protein precipitation and solid phase extraction procedure for determination of colistin in human serum.....	113
Table 4.4	High-performance liquid chromatography with fluorescence detection method for measuring colistin in human serum	119
Table 4.5	Recovery of total colistin (A and B) was evaluated using QC samples at four concentration levels. (n=4)	120
Table 4.6	Linearity of inter-day calibration samples. (n=3)	121
Table 4.7	The intra-day accuracy and precision of total colistin (A and B) were evaluated using QC samples at four concentration levels (n=4).....	122
Table 4.8	The inter-day accuracy and precision for total colistin (A and B) were evaluated using QC samples at four concentration levels (n=4).....	123
Table 4.9	Stability for total colistin (A and B) was evaluated using QC samples at four concentration levels.	125
Table 4.10	Stability for colistin methanesulfonate sodium.....	126
Table 4.11	Comparison of the HPLC-FLD method with the previous method measuring colistin in human plasma.	129
Table 4.12	Characteristics of included studies.....	131
Table 4.13	Demographic and clinical data of enrolled patients	139
Table 4.14	Summary of sample collection.....	140
Table 4.15	The colistin trough concentration in serum samples obtained from Malaysian critically ill patients at steady state.....	141
Table 4.16	Summary of published literature reports on colistin pharmacokinetics.....	143

Table 4.17	A comparison of demographic data for the model development and validation groups	144
Table 4.18	Statistic between structural models of one-, two- and three-compartment models	145
Table 4.19	Statistic between covariate model.....	146
Table 4.20	Population pharmacokinetics parameter in the Malaysian critically ill patients.	153
Table 4.21	Comparison of colistin population pharmacokinetics parameters obtained with previous population pharmacokinetics studies.....	154
Table 4.22	Patient 1 with colistin trough concentration higher than the target concentration	155
Table 4.23	Pharmacokinetics parameters of colistin.....	156
Table 4.24	Candidate dosage regimens of CMS for Patient 1	157

LIST OF FIGURES

	Page
Figure 1.1 The trend of multidrug-resistant organisms has changed over time in Malaysia	2
Figure 1.2 The trend of Gram-negative bacteria resistant to carbapenems (CRE) has changed over time in Malaysia.....	2
Figure 1.3 Conceptual framework of population PK model of colistin.	10
Figure 2.1 Chemical structure of polymyxin.....	18
Figure 2.2 Chemical structure of CMS and colistin (polymyxin E).....	19
Figure 2.3 An outline of CMS and colistin's disposition.....	29
Figure 3.1 Workflow of the study	53
Figure 3.2 Preparation of working standard solutions of colistin sulphate and polymyxin B (internal standard).	60
Figure 3.3 Solid phase procedure (SPE) method by Gobin <i>et al.</i> (2010).....	63
Figure 3.4 Optimisation of sample pre-treatment for colistin.	69
Figure 3.5 Workflow of population pharmacokinetics modelling development and validation	77
Figure 3.6 PRISMA flow chart.	80
Figure 3.7 Flow chart of subject recruitment and blood drawing process	86
Figure 4.1 Mass spectrometry chromatogram of the mobile phase compositions tested in isocratic mode.....	99
Figure 4.2 Mass spectrometry chromatogram in gradient mode.	99
Figure 4.3 A mass spectrometry chromatogram obtained using optimised gradient elution.....	100

Figure 4.4	Mass spectrometry chromatogram of colistin A and colistin B when the column temperature was set A: 30°C, B: 40°C, C: 45°C, D: 50°C.	101
Figure 4.5	Mass spectrometry spectrum of precursor and product ions in positive ionisation mode (ESI+).	104
Figure 4.6	Mass spectrometry spectrum of precursor and product ions in negative ionisation mode (ESI-).	106
Figure 4.7	Optimisation of collision energy voltage.	107
Figure 4.8	Chromatogram peak obtained with SPE Oasis-HLB.	110
Figure 4.9	Chromatogram peak obtained with SPE C18.	111
Figure 4.10	Chromatogram peak was obtained using protein precipitation with the SPE procedure, according to a study by Li <i>et al.</i> (2001)	112
Figure 4.11	Chromatogram peak of analytes obtained using a) column C-8 and b) column C-18.	114
Figure 4.12	Chromatogram peaks were obtained when adjusting the composition of acetonitrile in the mobile phase.	115
Figure 4.13	Chromatogram peaks were obtained when adjusting the composition of tetrahydrofuran in the mobile phase.	116
Figure 4.14	Chromatogram peaks were obtained when adjusting different flow rates.	117
Figure 4.15	Chromatogram peak obtained under optimal HPLC-FLD method..	118
Figure 4.16	A chromatogram was obtained for the selectivity and specificity test using the optimal HPLC-FLD method..	124
Figure 4.17	Chromatogram peak obtained from patients treated with intravenous CMS under optimal HPLC-FLD method.	128
Figure 4.18	Quality assessment of pharmacokinetic studies.	134
Figure 4.19	Structural design of the two-compartmental model of colistin.	145
Figure 4.20	An observed-predicted plot of the final model for population and individual	148

Figure 4.21	Marginal parameter values of the final model	148
Figure 4.22	The convergence plot of the final model.....	149
Figure 4.23	Normalised prediction distribution error (NPDE) for the final model.....	150
Figure 4.24	Diagnostic goodness-of-fit plots of the individual colistin prediction vs actual concentration plot (A) developed model dataset and (B) validation model dataset for colistin.	151
Figure 4.25	Prediction-corrected visual predictive checks of expected concentrations and their 95% CI (simulated 5 th , 50 th and 95 th percentiles).	152
Figure 4.26	Plasma colistin concentration-time plot of a patient receiving 0.5MIU 12 hourly	158
Figure 4.27	Plasma colistin concentration-time plot of a patient receiving 0.6MIU 12 hourly	158
Figure 4.28	Plasma colistin concentration-time plot of a patient receiving 1.2MIU 24 hourly	159
Figure 4.29	Plasma colistin concentration-time plot of a patient receiving 1.3MIU 24 hourly	159

LIST OF SYMBOLS

α	Alpha
β	Beta
γ	Gamma
$t_{1/2}$	Half-life
$t_{1/2\alpha}$	Distribution half-life
$t_{1/2\beta}$	Terminal half-life
μ	Micro
μg	Microgram
μL	Microliter
μm	Micrometer
$\mu\text{g/mL}$	Microgram per milliliter
%	Percentage
>	More than
-	Negative
+	Positive
$^{\circ}\text{C}$	Degree of Celsius
pH	Potential of hydrogen
pKa	Acid dissociation constant
Q	Intercompartmental clearance

LIST OF ABBREVIATIONS

ACN	Acetonitrile
AFC	Adaptive feedback control
AJS ESI	Agilent jet stream electrospray ionisation
AKI	Acute kidney injury
ARC	Augmented renal clearance
CE	Collision energy voltage
CI	Confidence interval
CL	Clearance
C _{min}	Minimum concentration
C _{max}	Maximal concentration
C _{ssave}	Average concentration at steady state
CMS	Colistin methanesulfonate sodium
CRE	Carbapenem resistant <i>enterobacteriaceae</i>
CrCl	Creatinine clearance
CL _r	Renal clearance
CL _{RCMS}	CMS renal clearance
CRRT	Continuous renal replacement therapy
CVVHDF	Continuous venovenous hemodiafiltration
CV	Coefficient of variation
ESBL	Extended-spectrum beta-lactamase
ESI	Electrospray ionisation
FMOC-CL	9-Fluorenylmethyl chloroformate
fm	Fraction of CMS converted to colistin
GFR	Glomerular filtration rate
GNB	Gram negative bacilli
h	hour
HD	Hemodialysis
HDW	High dependency ward
HLB	Hydrophilic-lipophilic balance
HPLC	High performance liquid chromatography
ICU	Intensive care unit

IT2B	Iterative-2-stage Bayesian parametric
IV	Intravenous
IIV	Inter-individual variability
IOV	Inter-occasional variability
L	Litre
L-Dab	L-diaminobutyric acid
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
LLOQ	Lower limit of quantitation
LOD	Limit of detection
LPS	Lipopolysaccharide
M	Molar
MDR	Multidrug-resistant
MIC	Minimum inhibitory inhibition
MIU	Million international unit
min	Minute
MRM	Multiple reaction monitoring
MS	Mass spectrometry
MS/MS	Tandem mass spectrometry
NPAG	Nonparametric adaptive grid
NR	Not reported
OPA	Orthophtalaldehyde
PK	Pharmacokinetic
PD	Pharmacodynamic
QC	Quality control
QTOF- LC/MS	Quadrupole time-of-flight liquid chromatography mass spectrometry
SIRS	Systemic inflammatory response syndrome
SD	Standard deviation
SPE	Solid phase extraction
SRM	Single reaction monitoring
TDM	Therapeutic drug monitoring

THF	Tetrahydrofuran
TLC	Thin layer chromatography
T _{max}	Time to reach maximal plasma concentration
UHPLC	Ultra-high-performance liquid chromatography
UI	Uncertainty interval
UV	Ultraviolet
V _d	Volume of distribution
V	Voltage
v	Volt
v/v	Volume per volume
XDR	Extended drug-resistant

LIST OF APPENDICES

Appendix A	Jawatankuasa Etika Penyelidikan Manusia USM (JPeM)
Appendix B	Ethics Approval Medical Research and Ethics Committee Ministry of Health (MREC)
Appendix C	Written Informed Consent Form
Appendix D	Case Report Form (CRF)
Appendix E	List of Publications
Appendix F	List of Research Presentations.

**MEMBANGUNKAN TERAPI INDIVIDU COLISTIN MELALUI APLIKASI
MODEL FARMAKOKINETIK UNTUK PESAKIT KRITIKAL MALAYSIA
MENGUNAKAN HPLC-FLD**

ABSTRAK

Colistin adalah antibiotik yang digunakan sebagai pilihan terakhir untuk merawat jangkitan bakteria. Disebabkan ketoksikannya, colistin diberi dalam bentuk prodrug yang tidak aktif, colistin methanesulfonate sodium (CMS). Penukaran CMS kepada colistin *in vivo*, yang berbeza-beza membawa kepada variasi dalam kepekatan colistin di dalam plasma dan parameter farmakokinetik bagi pesakit kritikal. Ketepatan kaedah analisa kepekatan colistin adalah diperlukan untuk menjayakan kajian farmakokinetik. Colistin mempunyai julat terapeutik yang sempit dan perlu dipantau untuk pengoptimuman dos. Oleh itu, kajian ini bertujuan, untuk membangunkan dos yang diperibadikan untuk colistin dengan menggunakan model farmakokinetik untuk pesakit yang kritikal di Malaysia. Kajian ini telah diluluskan oleh Jawatankuasa Etika Penyelidikan Manusia, Universiti Sains Malaysia, dan Jawatankuasa Penyelidikan and Etika Penyelidikan Perubatan, Kementerian Kesihatan Malaysia. Kaedah kromatografi cecair berprestasi tinggi dengan pengesanan pendarfluor (HPLC-FLD) telah dibangunkan dan divalidasikan untuk pengukuran kepekatan colistin dalam serum manusia. Kaedah yang telah divalidasikan ini kemudiannya digunakan untuk analisis serum pesakit kritikal yang menerima rawatan antibiotik CMS. Farmakokinetik populasi untuk colistin telah dimodelkan dengan pendekatan bukan parametrik menggunakan perisian Pmetrics. Model farmakokinetik yang telah dibangunkan akan digunakan untuk mengoptimumkan dos terapeutik ubat bagi pesakit secara individu. Keluk penentukuran linear diperolehi untuk mengukur colistin dalam kepekatan 0.3

hingga 8 µg/mL dengan kesesuaian yang baik ($r^2 = 0.9993$). Kaedah analisis ini telah mengukur dengan tepat kepekatan colistin dalam serum tanpa hidrolisis CMS kepada colistin *in vitro* yang ketara diperhatikan semasa prosedur. Ketepatan kaedah analisis ini diperolehi antara 98% hingga 100%. Dalam kebanyakan pesakit, kepekatan palung adalah lebih tinggi daripada purata kepekatan semasa dalam keadaan mantap yang disyorkan (2 µg/mL) dan ianya boleh mengakibatkan nefrotoksisiti. Algoritma Grid Adaptif Bukan Parametrik dalam perisian Pmetrics telah digunakan untuk membangunkan model farmakokinetik colistin menggunakan data meta-analisis daripada 15 kajian farmakokinetik. Pengesahan luaran model akhir telah dilakukan dalam 25 pesakit (data Malaysia dan meta-analisis). Farmakokinetik colistin diterangkan dengan baik oleh model dua bahagian dengan penghapusan tertib pertama. Pengesahan model telah dinilai dengan menggunakan plot terhadap kepekatan yang diukur untuk individu berbanding kepekatan kolistin yang diramalkan dimana R-kuadrat adalah 0.974. Model farmakokinetik colistin kemudiannya digunakan untuk pengoptimuman dos terapeutik ubat pesakit secara individu. Penggunaan pendekatan model-bermaklumat yang memfokuskan pada ubat yang diperibadikan boleh membantu mencapai ketepatan pengindividuan dos.

DEVELOPING INDIVIDUALISED THERAPY FOR COLISTIN THROUGH APPLICATION OF PHARMACOKINETIC MODEL TAILORED FOR CRITICALLY ILL MALAYSIAN PATIENTS UTILIZING THE HPLC-FLD

ABSTRACT

Colistin is an antibiotic used as a last option to treat bacterial infections. Due to its toxicity, colistin is administered in the form of an inactive prodrug, colistin methanesulfonate sodium (CMS). The conversion of CMS to colistin *in vivo* varies greatly, leading to variations in plasma colistin concentration and pharmacokinetic parameters in critically ill patients. A novel analytical method is necessary for any pharmacokinetic studies to succeed. Colistin has a narrow therapeutic window and needs to be monitored for dose optimisation. Therefore, this study aimed to develop personalised medicine for colistin using a pharmacokinetic model for Malaysian critically ill patients. The Human Research Ethics Committee of Universiti Sains Malaysia and the Malaysian Ministry of Health Research Ethical Committee approved the study. The high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method was developed and validated to measure colistin in human serum. This validated method was then used to analyse serum from critically ill patients receiving CMS. Colistin population pharmacokinetics was modelled with a nonparametric approach using Pmetrics software. The constructed pharmacokinetic model of colistin was then applied to optimise individual patient therapeutic drug doses. Linear calibration curves were obtained for colistin concentrations of 0.3 to 8 µg/mL, with good fit ($r^2 = 0.9993$). This analytical method accurately measured the amount of colistin in serum, with no significant hydrolysis of CMS into colistin *in*

vitro observed during the procedure. The accuracy ranged from 98% to 100%. In most patients, the trough concentration was higher than the recommended average steady-state concentration (2 µg/mL) and may be associated with nephrotoxicity. The Non-Parametric Adaptive Grid algorithm within Pmetrics software was used to develop a colistin pharmacokinetic model using meta-analysis data from 15 pharmacokinetic studies, and external validation of the final model was performed in 25 subjects (Malaysian and meta-analysis data). A two-compartment model with first-order elimination best describes colistin pharmacokinetics. Model validation was assessed by using a plot of observed versus individual predicted colistin concentration, and an R-squared of 0.974 was obtained in the validation group. The colistin pharmacokinetic model was then implemented for individual patient therapeutic drug dose optimisation. Applying a model-informed approach, focusing on personalised medicine, may help achieve precise dose individualisation.

CHAPTER 1

INTRODUCTION

1.1 Overview

Nosocomial infections cause high mortality and morbidity, particularly in patients who are critically ill (Haque *et al.*, 2018). The widespread nosocomial infections of multidrug-resistant Gram-negative bacteria (MDR GNB), including extended-spectrum β -lactamases (ESBLs), for example, *Escherichia coli*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*, have raised significant concern (Morris & Cerceo, 2020). The effectiveness of many existing antimicrobials against these organisms has significantly decreased, and treatment options have become limited (Tosi *et al.*, 2018). Carbapenems are the first-line therapy in critically ill patients with MDR GNB. Unfortunately, *Enterobacteriaceae* isolates have developed resistance to carbapenems (Meletis, 2016). The number of carbapenem-resistant *enterobacteriaceae* (CRE) isolates is increasing alarmingly (Logan & Weinstein, 2017).

In Malaysia, there has been a noticeable increase in MDR GNB, specifically those demonstrating resistance to carbapenems or colistin due to ESBL or plasmid-mediated colistin resistance (Annual Report IPC, 2022), as shown in Figures 1.1 and 1.2. Polymyxin antibiotics, such as colistin, are increasingly prescribed to combat these pathogens despite their potential to induce nephrotoxicity (Vaara, 2019).




Figure 1.1 The trend of multidrug-resistant organisms has changed over time in Malaysia. (Adapted from Annual Report IPC, (2022))




Figure 1.2 The trend of Gram-negative bacteria resistant to carbapenems (CRE) has changed over time in Malaysia. (Adapted from Annual Report IPC, (2022))

Treating infections in critically ill patients is becoming more challenging because of the prevalence of resistant bacteria to multiple drugs (Tosi *et al.*, 2018). Additionally, the antibiotic concentration could be affected by dynamic physiological changes in critically ill patients (Parker, Sime & Roberts, 2015; Nation *et al.*, 2017). The standard antibiotic regimen used to treat critically ill patients may be inadequate (Roberts, Roger & De Waele, 2019).

Critically ill patients exhibit greater pharmacokinetic variability than non-critically ill patients, particularly for hydrophilic antibiotics like aminoglycosides, β -lactam, glycopeptide, and linezolid (Abdul-Aziz *et al.*, 2020). In critically ill patients, the volume of distribution and drug clearance of β -lactam antibiotics can be twice as high as in non-critically ill patients (Abdul-Aziz *et al.*, 2020). Hence, optimising antibiotic therapy for ICU patients poses a significant challenge for managing doctors. The use of therapeutic drug monitoring (TDM) to personalise antibiotic treatment for critically ill patients is now justifiable. This is due to the improved understanding of the relationships between antibiotic dose, pharmacokinetic/pharmacodynamic (PK/PD) exposure, and patient outcomes.

1.2 Problem statement

Colistin use in critically ill patients has increased due to the rise in MDR GNB and the lack of new antibacterial medication classes developed in recent years. When colistin became available, it was known to be toxic. Colistin methanesulfonate sodium, a less toxic prodrug for intravenous injection, was developed to minimise its toxicity. When using CMS, it is important to note that it is converted slowly to colistin in the

body. The initial low concentration at the start of treatment may result in inadequate bacterial killing (Plachouras *et al.*, 2009). Colistin has been found to have a prolonged half-life (14 hours) in individuals who are critically ill (Plachouras *et al.*, 2009) than in patients with cystic fibrosis (10 hours) (Li *et al.*, 2003) and healthy individuals (3 hours) (Couet *et al.*, 2011). These findings indicated delayed attainment of steady-state colistin concentrations in critically ill populations (Plachouras *et al.*, 2009; Mohamed *et al.*, 2012; Karaiskos *et al.*, 2015). Owing to these issues, most current guidelines recommend applying CMS as a loading dosage prior to the maintenance dose (Nation *et al.*, 2016; Tsuji *et al.*, 2019). However, this may not always lead to sufficient colistin plasma levels (Ehrentraut *et al.*, 2020).

Optimising the colistin dosage in critically ill patients to achieve adequate plasma levels has proven difficult. Due to rapid fluctuations in renal function, volume status, and pathophysiology, variability in colistin plasma levels has been observed (Leuppi-Taegtmeyer *et al.*, 2019; Kristoffersson *et al.*, 2020; Ram *et al.*, 2021). Colistin has a narrow therapeutic window (2-4 µg/mL) (Nation *et al.*, 2017). Nephrotoxicity due to colistin is more prevalent when the minimum concentration (C_{min}) of colistin exceeds 2.4 µg/mL (Sorlí *et al.*, 2013; Forrest *et al.*, 2017). Consequently, it may be potentially harmful to use colistin without TDM. It may be helpful that colistin therapy is adjusted based on blood concentration to optimise the balance between the benefits and risks of treatment. High-performance liquid chromatography (HPLC) measures colistin levels in plasma but is not commonly performed in Malaysia. Liquid chromatography-mass spectrometry (LC-MS) methods for colistin assays are expensive and require skilled personnel, making them impractical in smaller settings (Gobin *et al.*, 2010; Gikas *et al.*, 2013). High-

performance liquid chromatography with fluorescence detection (HPLC-FLD) has been extensively used for colistin analysis (Li *et al.*, 2001; Chepyala *et al.*, 2015; Hanai *et al.*, 2018). The colistin levels of critically ill patients receiving CMS treatment were measured using the HPLC-FLD method in this current study.

Recent studies reported by Holford, Ma & Metz (2020) and Wicha *et al.* (2021) that TDM strategies are frequently ineffective or inferior. This is related to the TDM approach that defines therapeutic ranges within which the concentration is expected to be safe and effective. Therapeutic drug monitoring sampling should be conducted when the patient reaches a steady state. Therefore, TDM sampling for drugs with a long half-life will take place on Day 2 or 3 of therapy. In cases of infection, the pharmacokinetic-pharmacodynamic (PK/PD) target should be achieved as early as possible. In TDM, sampling time is crucial; if a sample is taken outside a predefined accepted window time, it cannot be interpreted accurately. Hence, the concept of target concentration intervention has been introduced, where defined targets instead of ranges were used (Holford, Ma & Metz, 2020). The prediction of drug concentration using pharmacometrics models with PK/PD targets might enhance the attainment of individual targets (Neely *et al.*, 2018). The advantage of this approach, Bayesian estimation of the pharmacokinetics (PK) parameter can be done using any timed plasma sample as long as the sampling is accurately documented (Alihodzic *et al.*, 2020).

Our understanding of CMS and colistin population PK has significantly progressed in the past decade (Karaiskos *et al.*, 2015; Kristoffersson *et al.*, 2020). Extensive research, primarily using a parametric approach, has been conducted. The

pharmacokinetics and plasma levels of colistin exhibit substantial variation among critically ill patients, making it challenging to achieve a normal (Gaussian) distribution. Therefore, a nonparametric method may be a more suitable approach to study population pharmacokinetics in this patient population. Although limited, some studies have explored the use of nonparametric methods (Mathew *et al.*, 2022). This study, therefore, employed a nonparametric approach to investigate the population pharmacokinetics of colistin in critically ill Malaysians. The need for further research in this area is urgent to optimise antibiotic dosing using pharmacokinetic modelling combined with software programs such as Pmetrics to calculate individualised doses. This approach has the potential to enhance the accuracy of antibiotic dosing and improve the clinical outcomes of the patients.

1.3 Objectives

1.3.1 General objective

This study aims to develop personalised medicine for colistin using a pharmacokinetic model for Malaysian critically ill patients.

1.3.2 Specific objectives

1. To develop a high-performance liquid chromatography method for quantification of colistin to be used in pharmacokinetics study.
2. To develop a pharmacokinetic model of colistin using meta-analysis data from previous pharmacokinetics studies.
3. To validate the developed pharmacokinetic model using Malaysian critically ill patient data.
4. To develop a personalised dosage optimisation using population pharmacokinetic modelling and simulation.

1.4 Justification of the study

Colistin's therapeutic window is narrow, ranging from 2-4 µg/mL. Improper dosing of colistin can lead to an increased incidence of colistin resistance or toxicity (Nation *et al.*, 2017). Accurate dosage prediction depends on understanding pharmacokinetic variability and measuring it in relation to easily obtainable clinical covariates (Wicha *et al.*, 2021). It is possible to achieve this using population pharmacokinetic models. Population PK models are applied to investigate potential causes of patient exposure variability and determine patients' drug exposure time course. They can be used to simulate different dosage regimens to optimise the achievement of the PK/PD target. Individual PK parameters could be estimated based on available clinical covariates. Personalised dosage optimisation can be determined by using the individual's estimated PK parameters (Holford, Ma & Metz, 2020; Wicha *et al.*, 2021).

There are two pharmacokinetic modelling approaches: parametric and nonparametric, based on the assumption of parameter distribution (Goutelle *et al.*, 2022; Guidi, Csajka & Buclin, 2022). Most pharmacokinetic data for colistin in critically ill patients is derived from a parametric approach. In parametric models, the PK parameter probability distributions are represented by parameters like mean and covariances, describing normal or lognormal distribution assumptions in the population study. Unlike parametric models, non-parametric models have a discrete distribution with no predefined shape. Continuous functions cannot describe the statistical distribution of the model parameter values in the population (Goutelle *et al.*, 2020). They are used to pool and analyse data from groups of patients. The parameter

estimate consists of individual parameters and a probability distribution without pre-existing assumptions about its shape (de Velde *et al.*, 2018).

The nonparametric method utilises an exact likelihood function, whereas the parametric method uses an approximation. The nonparametric approach is chosen for its advantages over parametric methods in identifying unexpected sub-populations or outliers (Jelliffe *et al.*, 2000). Only one study so far used a nonparametric approach, conducted by Mathew *et al.* (2022). Therefore, this current study developed a pharmacokinetic model with a nonparametric approach using data from previous studies on critically ill patients. It incorporates local data and other relevant parameters to help doctors determine the best dosage for individual patients.

1.5 Conceptual framework

Figure 1.3 illustrates the conceptual framework for the population pharmacokinetics model of colistin in critically ill patients, highlighting co-variates that may influence colistin concentration in plasma. The covariates that may also influence outcomes include the patient's comorbidities, hypoalbuminemia, extracorporeal therapies (e.g., renal replacement therapy), fluid management, post-surgical drainage, sepsis, mechanical ventilation, and others investigated in this study.




Figure 1.3 Conceptual framework of population PK model of colistin.

1.6 Significance of the study

The current dosing regimens for colistin used in the treatment of GNB infections are unlikely to attain the desired plasma concentration or may potentially increase the risk of toxicity. Since colistin has a narrow therapeutic range and patient severely ill are more prone to have substantial changes in their condition, it is necessary to monitor blood colistin levels to ensure the target concentration is met. Personalised colistin medicine aims to achieve specific PK/PD targets, reduce bacterial resistance, and minimise antibiotic toxicity. Using software to tailor antibiotic concentrations for individual patients can improve dosing accuracy in critically ill patients.

CHAPTER 2

LITERATURE REVIEW

2.1 Introduction

Critically ill patients are prone to infection due to invasive procedures like intubation and mechanical ventilation, as well as vascular access (Blot *et al.*, 2022). They have more chronic comorbid disorders, severe acute physiological derangements, and immunosuppression and are subjected to broad-spectrum antibiotics, causing selection and colonisation pressure in comparison to general ward patients (Jolivet *et al.*, 2020). Because critically ill patients have severe physiological imbalances, they are more vulnerable to MDR GNB infections and may not receive an optimal dosage of antimicrobial therapy (Bonten, 2012; Tängdén *et al.*, 2017; Heffernan *et al.*, 2018; Jolivet *et al.*, 2020).

Antibiotic concentrations may be altered due to extreme physiological derangements, life-saving medical interventions, or the natural course of critical illness (Abdul-Aziz *et al.*, 2015; Cotta, Roberts & Lipman, 2015). Dosing for antibiotics in this population is challenging and not as straightforward as in the general ward (Sime, Roberts & Roberts, 2015). Improving antibiotic therapy in the ICU can be challenging for various reasons, especially when dealing with infections caused by polymyxin-only susceptible GNB.

2.2 Critically ill patients

2.2.1 Definition

Critically ill patients are individuals with life-threatening conditions requiring constant treatment and monitoring. In this current study, critically ill patients are defined as individuals with possibly life-threatening conditions, single or multiple organ failure, who receive medical treatment in a high dependency ward (HDW) or ICU for the purpose of intensive care monitoring and organ support such as haemodynamic, renal, respiratory, neurological and others (Sakr *et al.*, 2018; Evans *et al.*, 2021). Because of the widespread use of invasive devices for diagnosis and treatment, patients in critical condition have a greater chance of acquiring life-threatening infections, leading to sepsis. According to a recent analysis by Rudd *et al.* (2020) an estimated 48.9 million (95% uncertainty interval [UI] 38.9–62.9) cases of sepsis, and there have been 11 million (95% UI 10.1–12.0) sepsis-associated mortality were reported globally, comprising 19.7% (95% UI 18.2–21.4) of all mortality reported to be caused by sepsis.

Sepsis is a life-threatening organ failure caused by a dysregulated immune response to infection, commonly leading to ICU admission (Sakr *et al.*, 2018). Septic shock is a severe form of sepsis that involves significant dysfunction in circulatory, cellular, and metabolic systems, increasing the risk of death compared to sepsis alone (Singer *et al.*, 2016). Controlling the pathogen's source and providing early, appropriate antibiotic therapy is vital for those who are severely ill and have infections (Paul *et al.*, 2010).

2.2.2 Antibiotic pharmacokinetics alteration in the critically ill patients

Dynamic physiological alterations experienced by severely ill patients, drugs (hydrophilicity and lipophilicity of the compound, drug interaction), disease conditions (organ dysfunction, acute phase response), and therapeutic intervention (fluid resuscitation, extracorporeal therapy) can significantly affect antibiotics pharmacokinetics (Parker, Sime & Roberts, 2015; Monogue, Kuti & Nicolau, 2016; Tosi *et al.*, 2018).

Sepsis and septic shock resulting from a severe infection can lead to multiple organ failure and pathophysiological modifications, which may impact the PK/PD characteristics of antibiotics (Roberts, Roger & De Waele, 2019). Bacterial endotoxins trigger systemic inflammatory response syndrome (SIRS), characterised by inflammatory mediators damaging blood vessel lining. Resulting in vasoconstriction or vasodilation, blood flow changes, endothelial injury, and leaky capillaries (Singer *et al.*, 2016; Tosi *et al.*, 2018). Because of vascular endothelial damage and inflammation, capillary leakage occurs due to fluid shifts between blood vessels and tissues (Singer *et al.*, 2016; Tosi *et al.*, 2018). Resulting in an increased volume of distribution (V_d) of hydrophilic drugs.

The volume of distribution determines the relationship between dose and serum concentration. An increase in V_d can decrease the overall concentration of antibiotics in the blood (Roberts, Kumar & Lipman, 2017). Factors that might influence V_d include sepsis, shock, mechanical ventilation, changes in plasma protein binding, hypoalbuminemia (increased capillary leakage), extracorporeal therapy (e.g.,

renal replacement therapy), post-surgical drainage, burn injury, or fluid resuscitation (Blot, Pea & Lipman, 2014). Low plasma antibiotic concentrations can impact the required dosage amount. Severe sepsis is associated with organ failure, while septic shock is characterised by unresponsive hypotension requiring vasopressor support despite adequate fluid administration (Singer *et al.*, 2016). This condition may alter the antibiotic elimination half-life ($t_{1/2}$).

An antibiotic's elimination half-life is the time it takes for its concentration or total quantity to decrease by 50%. Antibiotic elimination half-life is directly related to antibiotic clearance (CL) and V_d , as shown by the equation below (Roberts & Lipman, 2009):

$$t_{1/2} = 0.693 \times V_d / CL$$

Antibiotic metabolism occurs predominantly in the liver and kidneys. Renal blood flow directly correlates with the kidneys' capacity to eliminate the medication (Roberts & Hall, 2013). Sepsis or septic shock may occur due to volume depletion caused by capillary leakage and increased vascular capacity by vasodilatation, leading to disruption of the renal blood flow (Jacobi, 2002). This disease process may also increase V_d , and reduced CL will likely increase $t_{1/2}$.

Pharmacokinetic parameters may be altered due to interventions by intensivists, such as fluid resuscitation and the use of vasopressors to enhance blood flow and renal perfusion, which help restore blood volume and improve cardiac function (Boucher, Wood & Swanson, 2006; Roberts & Lipman, 2009). The intervention process can impact various PK parameters of antibiotics, such as

decreased V_d and increased CL and is also likely to reduce $t_{1/2}$. Additional interventions, such as mechanical ventilation, extracorporeal therapy, and albumin administration, can potentially modify the PK characteristics of antibiotics (Boucher, Wood & Swanson, 2006; Roberts & Lipman, 2009; Blot, Pea & Lipman, 2014).

Critically ill patients may encounter dynamic physiologic changes that affect their pharmacokinetic parameters, resulting in a change in antibiotic concentration. Multiple factors may influence pharmacokinetics, making predicting an appropriate concentration more challenging.

2.3 Polymyxin antibiotic

In the absence of effective and safe therapy options, polymyxins serve as the primary treatment for carbapenem-resistant infections. Several new antibiotics and combinations have recently been approved to treat certain MDR and extensively drug-resistant (XDR) gram-negative bacteria. Examples of these antibiotics include ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, and cefiderocol. However, these new antibiotics are not yet available in many countries, especially in developing countries like Malaysia.

2.3.1 Chemical structure

Polymyxins are polypeptide antibiotics that consist of 5 different chemical properties substances (polymyxins A to E). Only Polymyxin B and Polymyxin E (colistin) are available for clinical options (Rhouma *et al.*, 2016; Poirel, Jayol &

Nordmann, 2017). Polymyxins consist of a cyclic structure formed by seven amino acids and a linear chain of three amino acids linked to a fatty acid group (Rhouma *et al.*, 2016; Poirel, Jayol & Nordmann, 2017). Polymyxin E and B differ by a single amino acid, D-leucine or D-phenylalanine, respectively, at position six of the peptide ring (Figure 2.1).

Colistin is an old antibiotic which was not widely used due to its adverse effects, especially nephrotoxicity (Mendes & Burdmann, 2010). To reduce its toxicity, the colistin molecule has undergone modifications and is now administered intravenously as a prodrug known as CMS (Figure 2.2) (Falagas & Kasiakou, 2006). Colistin methanesulfonate sodium is produced by reacting colistin's free γ -amino groups with formaldehyde and sodium bisulfite (Bergen *et al.*, 2006; He *et al.*, 2013). Colistin methanesulfonate sodium is not microbiologically active. After administration, it spontaneously hydrolyses in aqueous media and is converted into colistin and partially sulfomethylated derivatives in biological fluid (Bergen *et al.*, 2006)).

The primary constituents of colistin are colistin A and B (Figure 2.2), available for oral and topical use as colistin sulphate and intravenous formulation as CMS (Orwa *et al.*, 2001). Colistin (colistin sulphate or CMS) can also be administered as an inhalation (Li *et al.*, 2006). Colistin is polycationic, and CMS is a polyanion at a physiological pH of 7.4 (Li *et al.*, 2006; Bergen *et al.*, 2012). The α,γ -diaminobutyric acid residues are ionised at physiological pH. This causes colistin molecules, which carry a net positive charge, to interact with the lipid A's negatively charged phosphate

groups in the bacterial lipopolysaccharide (LPS) membrane (Nation, Velkov & Li, 2014).

Colistin methanesulfonate sodium is replaced by negatively charged methanesulfonate moieties at physiological pH, which are the main amines of the Dab residues. After administration, it must be converted to colistin to become active against bacteria (Bergen *et al.*, 2006). The molecular weight of colistin A is 1169 g/mol, and colistin B is 1155 g/mol. Colistin methanesulfonate sodium has a higher molecular weight due to five extra sulfomethyl groups, and the molecular weights of CMS A is 1635 g/mol, and CMS B is 1621 g/mol (Grégoire *et al.*, 2017). Colistin is a hydrophilic drug (Shah *et al.*, 2014) with basic properties (acid dissociation constant [pKa] of about 10) (Li *et al.*, 2005) and CMS is less basic than colistin (Yapa *et al.*, 2013).




Figure 2.1 Chemical structure of polymyxin.

Number 6 indicates the amino acid position on the structure, D-phenylalanine in polymyxin B, or D-leucine in polymyxin E (colistin) (Adapted from Rhouma *et al.* (2016)).




Figure 2.2 Chemical structure of CMS and colistin (polymyxin E). Amino group: α,γ -diaminobutyric acid residues. Fatty acid, R-6-methyloctanoic for CMS A and colistin A, 6-methylheptanoic acid for CMS B and colistin B (Adapted from Rhouma *et al.* (2016)).

2.3.2 Mechanism of antibacterial activity of polymyxins

Colistin's specific antibacterial mode of action in killing bacterial cells is unknown (Kaye *et al.*, 2016). Colistin's potent antibacterial action is driven by its interaction with the LPS molecules in the cytoplasmic membrane of GNB. This interaction destroys the membrane, allowing internal components to leak out and causing cell death (Vaara, 1992; El-Sayed Ahmed *et al.*, 2020).

2.4 Bioassay of colistin methanesulfonate sodium and colistin

A variety of methodologies have been reported for quantifying colistin in biological specimens: capillary electrophoresis (Kjærgaard Kristensen & Honoré Hansen, 1993), microbiological assay (Thomas, Thomas & Holloway, 1980; Leroy *et al.*, 1989), immunological assay (Kitagawa *et al.*, 1985), thin-layer chromatography (TLC) (Thomas & Holloway, 1978), and HPLC (Dagla *et al.*, 2019).

2.4.1 Microbiological assay

Microbiological assays were previously used in pharmacokinetic research to determine dosage regimens for prescribing information. However, these approaches are inadequate in sensitivity and selectivity, and the processes take considerable time. The microbiological method for assaying CMS and colistin uses a clinical isolate such as *Bordetella bronchiseptica* (Thomas, Thomas & Holloway, 1980) or *Escherichia coli* (Wootton, Holt & Macgowan, 2005) as indicator organism. The indicator strain was evenly distributed on the surface of the agar medium, and then standard antibiotic

concentrations were added to the agar. After that, the plates underwent a 24-hour pre-incubation at 37°C. Li (2005) expressed concerns about the method's inability to differentiate between CMS and colistin during *in vitro* conversion. *In vitro*, the conversion of CMS to colistin was slower than *in vivo*, and the development of colistin from its intermediates was more rapid (Milne *et al.*, 2003). According to Li (2005), samples containing partially methanesulfonate intermediates in the agar plate will exhibit a more rapid colistin formation during incubation than samples containing CMS used for calibration curves. This suggests that previous dosage recommendations based on microbiological assay pharmacokinetic data may have been inaccurate.

2.4.2 High-performance liquid chromatography with fluorimetry detection (HPLC-FLD)

The advancement of HPLC analytical methods has considerably enhanced our comprehension of CMS and colistin pharmacokinetics. These analytical methods can separate and accurately measure colistin and CMS concentration in biological samples. Colistin has low ultraviolet (UV) absorbance and has no native fluorescent properties, so its analysis in biological samples using HPLC requires derivatisation with fluorescent reagents. In the colistin assay, derivative reagents such as orthophthalaldehyde (OPA), 9-fluorenylmethyl chloroformate (FMOC-Cl), and dansyl chloride were used. The HPLC method with fluorimetry detection demonstrated high sensitivity and accuracy in quantifying the concentration of colistin within the clinically relevant analytical range of 0.05–20 µg/mL (Nation *et al.*, 2016; Hanai *et al.*, 2018). Liquid chromatography methods require derivatisation and have relatively long run times, typically ranging from 9 to 35 minutes for fluorimetry detection (Le Brun, de Graaf & Vinks, 2000; Li *et al.*, 2001, 2002; Reed *et al.*, 2001). Table 2.1

summarises the bioassay of CMS and colistin in biological fluid using HPLC with a fluorimetry detection method.

2.4.3 Liquid chromatography-tandem mass spectrometry (LC-MS)

Colistin detection via mass spectrometry provides great sensitivity and specificity without requiring a derivatisation procedure. A new and advanced method was developed to measure colistin in human biological fluid using the LC-MS systems (Gobin *et al.*, 2010), liquid chromatography-tandem mass spectrometry (LC-MS/MS) system (Jansson *et al.*, 2009; Dotsikas *et al.*, 2011; Leporati *et al.*, 2014) and Ultra-high-pressure liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) system (Tsai *et al.*, 2013). These newly developed methods were improvised to accelerate the analysis. The introduction of better pre-treatment procedures (Jansson *et al.*, 2009; Gobin *et al.*, 2010; Tsai *et al.*, 2013), using automated robotic liquid-handling workstations (Dotsikas *et al.*, 2011), and an alternative technique utilising hybrid quadrupole time-of-flight mass spectrometry (QTOF MS) combined with ultra-performance liquid chromatography (UPLC) (Gikas *et al.*, 2013), reducing the run time for LC-MS up to two minutes per analysis (Ma *et al.*, 2008; Dotsikas *et al.*, 2011).

The liquid chromatography-tandem mass spectrometry approach shortened the chromatographic method's run times. This method could also detect colistin levels two to seven times lower than those found using the fluorescence method. However, this instrument required trained personnel and mass spectrometry was not widely available. Table 2.2 summarises the bioassay of CMS and colistin in biological fluid using the LC-MS/MS method.

Table 2.1 Bioanalysis of CMS and/or colistin in biological fluid using HPLC with fluorimetry detection method.

Author	Sample	Sample Preparation	Internal Standard	Chromatography method				Total Run Time	Fluorimetry detection method		
		Protein Precipitation		LC	Column	Mobile Phase	Elution		Fluorescent reagent	Detection	Concentration Range
Le Brun, de Graaf & Vinks, (2000) (Colistin)	Human plasma, urine, sputum	MeOH-20% TCA (plasma, sputum), MeOH (urine)	-	HPLC	Novapack C18 (3.9x150 mm)	ACN, 0.01mol phosphate buffer (675:325 v/v)	Isocratic	26min	OPA	excitation 340nm, emission 440 nm	30µg/L-1mg/L
Reed <i>et al.</i> (2001) (Colistin)	Human plasma, urine, sputum	Perchloric acid, potassium hydroxide, hydrochloric acid, 9% sodium carbonate, proline, ethyl acetate (plasma, sputum). Water, perchloric acid, sodium phosphate, proline, ethyl acetate. (urine) (170min)	-	HPLC	Eclipse XDB-C8 (150x 4.8mm)	Solvent A: Water-0.1% TFA Solvent B: ACN-0.1% TFA	Gradient	18min	Dansyl chloride	excitation 350nm, emission 500nm	5-7µg/mL
Pinho <i>et al.</i> (2018) (Colistin)	Human plasma	0.1M sodium bicarbonate buffer, TCA	Amphetamine sulphate	HPLC	LiChroC ART Purospher Star C18 (55mmx4 mm, 3µm)	Solvent A: ACN Solvent B: Water	Gradient	17min	Dansyl chloride		0.09-9µg/mL

ACN: Acetonitrile; Fmoc-Cl: 9-fluorenylmethyl chloroformate; HPLC: High-performance liquid chromatography; MeOH: Methanol; mg/L: milligram/Liter; mm: millimetre; nm: nanometer; µg/mL: microgram/milliliter; OPA: Orthophthalaldehyde; v/v/v: volume/volume/volume; TCA: Trichloroacetic acid; XDB: eXtra Dense Bonding.

Table 2.1 Continued.

Author	Sample	Sample Preparation			Internal Standard	Chromatography method				Total Run Time	Fluorimetry detection method		
		Protein Precipitation	SPE			LC	Column	Mobile Phase	Elution		Fluorescent reagent	Detection	Concentration Range
			Column	Elution									
Li <i>et al.</i> (2001) (Colistin)	Human plasma	MeOH-10% TCA (50:50, v/v)	C18	Acetone 0.2M boric acid solution	Netilmicin	HPLC	Ultrashpere C18 (250x4.6 mm)	ACN-tetrahydrofuran-water (87:4:13 v/v)	Isocratic	35min	FMOC-CI	excitation 260nm, emission 315nm	0.1-4.0mg/L
Li <i>et al.</i> (2002) (CMS)	Rat plasma rat urine	MeOH-10% TCA (50:50, v/v)	C18	Acetone 0.2M boric acid solution	Netilmicin	HPLC	Ultrashpere C18 (250x4.6 mm)	ACN-tetrahydrofuran-water (50:30:20 v/v/v)	Isocratic	18min	FMOC-CI	excitation 260nm, emission 315nm	0.33-53.3mg/L (rat plasma), 0.25-40mg/L (rat urine)
Chepyala <i>et al.</i> (2015) (Colistin)	Human plasma	MeOH-20% TCA (50:50, v/v)	C18	Acetone	Polymyxin B1	HPLC	Poroshell 120 (100x2.1 mm, 2.7 µm)	ACN, tetrahydrofuran, water (82:2:16, v/v/v)	Isocratic	22min	FMOC-CI	excitation 260nm, emission 315nm	0.3-6.0µg/mL
Hanai <i>et al.</i> 2018) (Colistin)	Human plasma	MeOH-10% TCA (50:50, v/v)	C18	Acetone	Netilmicin	HPLC	Hydrosphere C18 (50x4.6, 5µm)	ACN/tetrahydrofuran/distilled water (50:14:20, v/v/v)	Isocratic	~9min	FMOC-CI	excitation 260nm, emission 315nm	0.1-8µg/mL

ACN: Acetonitrile; FMOC-CI: 9-fluorenylmethyl chloroformate; HPLC: High performance liquid chromatography; MeOH: Methanol; mm: milimeter; nm: nanometer; µg/mL: microgram/mililiter; mg/L: milligram/Liter; OPA: Orthophthalaldehyde; v/v/v: volume/volume/volume; TCA: Trichloroacetic acid